The Anti-Seizure Effect of Liraglutide on Ptz-Induced Convulsions Through its Anti-Oxidant and Anti-Inflammatory Properties

Basit Öğe Kaydı
dc.authorscopusid57189713929
dc.authorscopusid57202425103
dc.authorscopusid55469991100
dc.contributor.authorErdogan M.A.
dc.contributor.authorErdogan A.
dc.contributor.authorErbas O.
dc.date.accessioned2023-03-22T19:47:45Z
dc.date.available2023-03-22T19:47:45Z
dc.date.issued2023
dc.departmentBelirleneceken_US
dc.description.abstractEpilepsy is a prevalent and frequently devastating neurological disorder defined by recurring spontaneous seizures caused by aberrant electrical activity in the brain. Over ten million people worldwide suffer from drug-resistant epilepsy. This severe condition requires novel treatment approaches. Both oxidative and nitrosative stress are thought to have a role in the etiology of epilepsy. Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue that is used to treat type-2 diabetes mellitus. According to recent studies, Liraglutide also shows neuroprotective properties, improving memory retention and total hippocampus pyramidal neuronal population in mice. The purpose of this investigation was to determine the anti-seizure and anti-oxidative effects of liraglutide in a pentylenetetrazole (PTZ)-induced rat model of epilepsy. 48 rats were randomly assigned to two groups: those who had electroencephalography (EEG) recordings and those who underwent behavioral assessment. Rats received either intraperitoneal (IP) liraglutide at two different dosages (3–6 mg/kg) or a placebo, followed by pentylenetetrazole (IP). To determine if liraglutide has anti-seizure characteristics, we examined seizure activity in rats using EEG, the Racine convulsion scale (RCS), the time of first myoclonic jerk (FMJ), and MDA, SOD, TNF-?, IL-1? and GAD-67 levels. The mean EEG spike wave percentage score was reduced from 75.8% (placebo) to 59.4% (lower-dose) and 41.5% (higher-dose). FMJ had increased from a mean of 70.6 s (placebo) to 181.2 s (lower-dose) and 205.2 s (higher-dose). RCS was reduced from a mean of 5.5 (placebo) to 2.7 (lower-dose) and 2.4 (higher-dose). Liraglutide (3 and 6 mg/kg i.p.) successfully decreased the spike percentages and RCS associated with PTZ induced epilepsy, as well as considerably decreased MDA, TNF-?, IL-1? and elevated SOD, GAD-67 levels in rat brain. Liraglutide significantly decreased seizure activity at both dosages when compared to control, most likely due to its anti-oxidant and anti-inflammatory properties. The potential clinical role of liraglutide as an anti-seizure medication should be further explored. © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.en_US
dc.identifier.doi10.1007/s11064-022-03736-4
dc.identifier.endpage195en_US
dc.identifier.issn03643190
dc.identifier.issue1en_US
dc.identifier.pmid36040609en_US
dc.identifier.scopus2-s2.0-85136923649en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage188en_US
dc.identifier.urihttps://doi.org/10.1007/s11064-022-03736-4
dc.identifier.urihttps://hdl.handle.net/20.500.14034/850
dc.identifier.volume48en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.journalNeurochemical Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEpilepsyen_US
dc.subjectGLP-1en_US
dc.subjectLiraglutideen_US
dc.subjectNeuroinflammationen_US
dc.subjectOxidative Stressen_US
dc.subjectSeizureen_US
dc.subject3,4 methylenedioxyamphetamineen_US
dc.subjectglucagon like peptide 1en_US
dc.subjectglutamate decarboxylase 67en_US
dc.subjectinterleukin 1betaen_US
dc.subjectliraglutideen_US
dc.subjectpentetrazoleen_US
dc.subjecttumor necrosis factoren_US
dc.subjectanticonvulsive agenten_US
dc.subjectantiinflammatory agenten_US
dc.subjectantioxidanten_US
dc.subjectliraglutideen_US
dc.subjectpentetrazoleen_US
dc.subjectsuperoxide dismutaseen_US
dc.subjecttumor necrosis factoren_US
dc.subjectanimal experimenten_US
dc.subjectanimal modelen_US
dc.subjectantiinflammatory activityen_US
dc.subjectantioxidant activityen_US
dc.subjectArticleen_US
dc.subjectartificial intelligenceen_US
dc.subjectbehavior changeen_US
dc.subjectbiochemical analysisen_US
dc.subjectbrain tissueen_US
dc.subjectelectric activityen_US
dc.subjectelectroencephalogramen_US
dc.subjectelectroencephalographyen_US
dc.subjectenzyme linked immunosorbent assayen_US
dc.subjectfrontal cortexen_US
dc.subjectgene expressionen_US
dc.subjectgeneral anesthesiaen_US
dc.subjecthippocampusen_US
dc.subjectinformation processingen_US
dc.subjectlipid peroxidationen_US
dc.subjectmaleen_US
dc.subjectmemory consolidationen_US
dc.subjectmouseen_US
dc.subjectnitrosative stressen_US
dc.subjectnonhumanen_US
dc.subjectoxidative stressen_US
dc.subjectpentylenetetrazole-induced convulsionen_US
dc.subjectraten_US
dc.subjectspike waveen_US
dc.subjectanimalen_US
dc.subjectdisease modelen_US
dc.subjectepilepsyen_US
dc.subjectmyoclonusen_US
dc.subjectseizureen_US
dc.subjectAnimalsen_US
dc.subjectAnti-Inflammatory Agentsen_US
dc.subjectAnticonvulsantsen_US
dc.subjectAntioxidantsen_US
dc.subjectDisease Models, Animalen_US
dc.subjectEpilepsyen_US
dc.subjectLiraglutideen_US
dc.subjectMiceen_US
dc.subjectMyoclonusen_US
dc.subjectPentylenetetrazoleen_US
dc.subjectRatsen_US
dc.subjectSeizuresen_US
dc.subjectSuperoxide Dismutaseen_US
dc.subjectTumor Necrosis Factor-alphaen_US
dc.titleThe Anti-Seizure Effect of Liraglutide on Ptz-Induced Convulsions Through its Anti-Oxidant and Anti-Inflammatory Propertiesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu